What are the indications, dosing guidelines, contraindications, and monitoring recommendations for doxepin?

Doxepin: Clinical Overview

Doxepin is a tricyclic antidepressant with two distinct clinical applications: low-dose formulations (1-6 mg) for insomnia and higher doses (75-300 mg) for depression and anxiety disorders. The dosing, monitoring, and safety considerations differ dramatically between these two indications.

Primary Indications

Low-Dose Doxepin (1-6 mg) - Insomnia

For chronic insomnia disorder, low-dose doxepin (3 or 6 mg) is recommended as a short-course pharmacologic option when cognitive behavioral therapy for insomnia (CBT-I) is unavailable or declined by the patient 1. This represents a second-line approach, as CBT-I demonstrates superior long-term outcomes compared to all pharmacologic interventions 1.

Low-dose doxepin works through selective H1-receptor antagonism at these doses, improving sleep maintenance and total sleep time without significant next-day residual effects 2, 3. The 3 mg and 6 mg doses showed efficacy in older adults, while the 6 mg dose was effective in younger adults 1.

Standard-Dose Doxepin (75-300 mg) - Depression and Anxiety

For depression and anxiety disorders, doxepin is indicated at substantially higher doses 4. The typical starting dose is 75 mg daily, with an optimal range of 75-150 mg/day for mild to moderate illness 4. More severe cases may require titration up to 300 mg/day, though additional benefit beyond this dose is rarely achieved 4.

Off-Label Uses

• Neuropathic pain: Doxepin can be considered as a secondary-amine tricyclic alternative, though nortriptyline or desipramine are preferred 5
• Chronic pain with depression: Demonstrated efficacy at approximately 200 mg/day 6
• Pruritus in dermatology: Most efficacious antipruritic available, typically at 10-25 mg/day 7

Dosing Guidelines

For Insomnia (Low-Dose)

• Starting dose: 3 mg at bedtime
• Maximum dose: 6 mg at bedtime
• Elderly/debilitated: Start at 3 mg; maximum 6 mg
• Duration: Short courses only; efficacy maintained up to 12 weeks in trials 2, 3
• Administration: Take within 30 minutes of bedtime; do not take within 3 hours of a meal 4

For Depression/Anxiety (Standard-Dose)

• Starting dose: 75 mg daily (can be divided or given once daily at bedtime)
• Mild symptoms: May use 25-50 mg/day
• Optimal range: 75-150 mg/day
• Severe illness: May increase gradually to 300 mg/day
• Maximum: 300 mg/day (150 mg if once-daily dosing)
• Elderly: Start at lower end of range; use caution 4
• Time to effect: Anti-anxiety effects appear before antidepressant effects; optimal antidepressant effect may take 2-3 weeks 4

Critical dosing consideration: There is massive interindividual variability in doxepin plasma levels—greater than 20-fold differences at fixed doses 8. Only 9% of patients achieve the historically cited "therapeutic range" of 150-250 ng/mL at standard doses 9.

Contraindications

Absolute Contraindications

• Glaucoma: Doxepin may trigger angle-closure attack in patients with anatomically narrow angles without patent iridectomy 4
• Urinary retention: Anticholinergic effects worsen this condition 4
• MAO inhibitor use: Concurrent or recent (within 14 days) use
• Hypersensitivity to doxepin or tricyclics

Relative Contraindications/Major Cautions

• Cardiac disease: Particularly ischemic heart disease or ventricular conduction abnormalities; obtain screening ECG in patients >40 years 5
• Respiratory compromise: COPD, asthma, sleep apnea 10
• Hepatic impairment: Reduce dose; maximum 2 mg for low-dose formulation 10
• Renal impairment: Dose adjustment needed; reduce to 5 mg over 24 hours if eGFR <30 mL/min (for parenteral formulations) 11
• Pregnancy/nursing: Not recommended; apnea and drowsiness reported in nursing infant 4
• Age <12 years: Safety not established 4
• Bipolar disorder risk: Screen patients before initiating; may precipitate manic episode 4

Monitoring Recommendations

Initial Assessment

• Cardiac screening: ECG in patients >40 years or with cardiac risk factors 5
• Bipolar screening: Detailed psychiatric history including family history of suicide, bipolar disorder, and depression 4
• Glaucoma assessment: Evaluate for narrow angles 4

Ongoing Monitoring

• Suicidality surveillance: Close monitoring during initial months and after dose changes, particularly in patients <25 years 4. Watch for anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, or mania 4.
• Anticholinergic effects: Monitor for dry mouth, blurred vision, constipation, urinary retention 4
• Sedation/confusion: Especially in elderly; may require dose reduction 4
• Cardiovascular effects: Blood pressure, heart rate; watch for hypotension, hypertension, tachycardia 4

Therapeutic Drug Monitoring (Standard-Dose Only)

Blood level monitoring should be considered for patients not responding to typical doses 7. Without monitoring, apparent treatment failures may actually represent inadequate dosing due to rapid metabolism 7, 8. A working range of 50-250 ng/mL (doxepin + desmethyldoxepin) is more realistic than the traditional 150-250 ng/mL range 9.

Pharmacogenetic Testing

Consider CYP2C19 and CYP2D6 genotyping when toxicity or lack of response occurs 12, 13:

• CYP2C19 poor/ultrarapid metabolizers: Consider alternatives (nortriptyline, desipramine) 12
• CYP2D6 ultrarapid metabolizers: Consider alternatives 12
• CYP2D6 poor metabolizers: Consider 50% dose reduction or alternatives 12

Key Safety Considerations

Black Box Warning

Increased risk of suicidal thinking and behavior in children, adolescents, and young adults (ages 18-24) with major depressive disorder and other psychiatric disorders 4. All patients require close monitoring for clinical worsening and suicidality, especially during initial treatment and dose changes 4.

Common Adverse Effects

• Most common: Drowsiness (tends to diminish with continued therapy), dry mouth, constipation 4
• Low-dose formulation: Headache and somnolence most common; no significant next-day residual effects 2, 3
• Cardiovascular: Hypotension, hypertension, tachycardia (less common than with other tricyclics) 14
• Other: Blurred vision, urinary retention, confusion, weight gain 4

Serious Risks

• Cardiac toxicity: QRS widening on ECG indicates severity of overdose; can be fatal 4
• Withdrawal syndrome: Gradual taper required after prolonged use to avoid withdrawal symptoms 4
• Bone marrow depression: Rare but monitor for agranulocytosis, leukopenia, thrombocytopenia 4
• Angle-closure glaucoma: Pupillary dilation may trigger attack 4

Drug Interactions

Significant alterations in oral clearance occur with concurrent medications 8:

• Enzyme inducers: Increase doxepin clearance (>3-fold difference)
• Enzyme inhibitors: Decrease doxepin clearance (>3-fold difference)
• CNS depressants/alcohol: Additive psychomotor impairment 10
• Cimetidine: Reduce zaleplon dose to 5 mg when co-administered (relevant for comparison agents) 10

Overdose Management

Critical manifestations include cardiac dysrhythmias, severe hypotension, convulsions, and CNS depression/coma 4. QRS duration ≥0.10 seconds indicates severity 4. Immediate actions:

1. Obtain ECG and initiate cardiac monitoring
2. Protect airway, establish IV access
3. Gastric lavage followed by activated charcoal (emesis contraindicated)
4. Sodium bicarbonate to maintain pH 7.45-7.55
5. Minimum 6 hours observation; extend if toxicity signs appear 4

Special Populations

Elderly

Start at low doses and titrate cautiously; elderly are more susceptible to confusion, oversedation, falls, and anticholinergic effects 4. For low-dose insomnia formulation, no dose adjustment beyond standard 3-6 mg range is specified, but monitor closely 10.

Hepatic Impairment

For low-dose formulation: Maximum 2 mg in severe hepatic impairment 10.

Renal Impairment

Dose adjustment required; extent of renal excretion not fully determined 4.

Clinical Pearls

• Administration timing: Take on empty stomach to maximize effectiveness 10
• Insomnia vs. depression: The dose difference is dramatic—6 mg vs. 75-300 mg; do not confuse indications
• Plasma level variability: 88% of patients fall below the traditional "therapeutic range" at standard doses 9; consider therapeutic drug monitoring for non-responders
• Avoid benzodiazepines: For chronic insomnia, guidelines advise against benzodiazepines due to harms outweighing benefits 1; low-dose doxepin is preferred if pharmacotherapy needed
• Gradual withdrawal: Taper slowly to avoid withdrawal symptoms after prolonged use 4
• Suicide risk unknown for low-dose: While standard-dose tricyclics carry black box warning, the suicide risk for low-dose doxepin as hypnotic is unknown and cannot be excluded 1